Trialkyne Linking Agents for Oligonucleotide Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for linking agents that can efficiently and safely conjugate oligonucleotide-based compounds, such as RNAi agents, to targeting ligands, while maintaining stability outside the target cell and being readily cleavable at the final site of action.
Innovation Solution
The development of trialkyne linking agents, which can be attached to oligonucleotides and subsequently linked to targeting ligands or other pharmacokinetic enhancers, facilitating the synthesis of oligonucleotide conjugates with improved yields and reduced impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional linking agents are used to conjugate oligonucleotide-based compounds to targeting ligands, then the conjugation can be achieved, but the reaction yields are low and toxic byproducts are generated
Solution Approach 1:
The patent employs trialkyne linking agents as intermediary compounds that facilitate the conjugation between oligonucleotide-based compounds and targeting ligands through copper-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry. The trialkyne structure serves as a modular mediator that enables high-yield conjugation while avoiding the formation of toxic byproducts associated with conventional linking methods
Solution Approach 2:
The invention changes the chemical parameters of the linking agent from conventional approaches to trialkyne-based structures with specific modular designs. This parameter change enables the use of copper-catalyzed click chemistry, which provides superior reaction yields and cleaner reaction profiles compared to traditional conjugation methods
2Stability of the object's composition
If the linkage chemistry is made stable outside the target cell, then the oligonucleotide remains protected in circulation, but it becomes difficult to cleave at the final site of action
Solution Approach 1:
The patent incorporates dynamic properties into the linking agent design by including cleavable bonds that respond to specific intracellular conditions. The trialkyne linker contains labile bonds such as disulfide bonds or ester bonds that remain stable in the extracellular environment but are readily cleaved by intracellular enzymes or reducing conditions, enabling the oligonucleotide to be released at the target cell
Solution Approach 2:
The linking agent exhibits different stability characteristics in different locations: high stability in extracellular circulation to protect the oligonucleotide, and localized cleavability at the intracellular target site. This spatial differentiation of stability properties is achieved through the molecular design of the trialkyne linker with conditionally labile bonds
3Ease of operation
If the linkage chemistry uses simple reaction conditions, then the conjugation process is easier to perform, but the chemical yields may be insufficient
Solution Approach 1:
The trialkyne linking agent serves as a specialized intermediary that enables conjugation under simplified reaction conditions while maintaining high chemical yields. The copper-catalyzed azide-alkyne cycloaddition chemistry provides both ease of operation and superior yield, resolving the trade-off between simplicity and productivity
Data Source
AI summary
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.